Inflammatory bowel disease can be caused by the dysfunction of the intestinal mucosal
barrier and dysregulation of gut microbiota. Traditional treatments use drugs to manage …

The clinical application of orally delivered probiotics as live therapeutics in the treatment of
colitis is hampered by suboptimal bacterial bioactivity and inadequate gut retention. Here …

Rapid advances in synthetic biology have fueled interest in engineered microorganisms that
can diagnose and treat disease. However, designing bacteria that detect dynamic disease …

The inflammatory bowel diseases (IBDs) are chronic inflammatory conditions, which are
increasing in prevalence worldwide. The IBDs are thought to result from an aberrant immune …

Despite the great progress of current bacterially based biotherapeutics, their unsatisfying
efficacy and underlying safety problems have limited their clinical application. Herein …

Microbiota‐based therapeutics offer innovative strategies to treat inflammatory bowel
diseases (IBDs). However, the poor clinical outcome so far and the limited flexibility of the …

Oral administration of probiotics is a promising method to alleviate inflammatory bowel
diseases (IBDs). However, gastrointestinal environmental sensitivity and inferior intestinal …

Inflammatory intestinal diseases such as Crohn's disease and ulcerative colitis have seen
an increase in their prevalence in developing countries throughout the current decade …

Inflammatory bowel disease (IBD) is a chronic inflammatory condition of gastrointestinal (GI)
tract with dysregulated mucosal immune functions and disturbed commensal ecosystem of …

The gut microbiota that inhabit our gastrointestinal tract are well known to play an important
role in maintaining human health in many aspects, including facilitating the digestion and …